|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1998-8-12
|
|
pubmed:abstractText |
To evaluate the trade-off of toxicity versus improved clinical outcome with interferon alfa-2b (IFN) administered concomitantly with a doxorubicin-containing regimen for the treatment of advanced follicular lymphoma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2339-44
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9667248-Adult,
pubmed-meshheading:9667248-Aged,
pubmed-meshheading:9667248-Antineoplastic Agents,
pubmed-meshheading:9667248-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9667248-Cyclophosphamide,
pubmed-meshheading:9667248-Decision Making,
pubmed-meshheading:9667248-Doxorubicin,
pubmed-meshheading:9667248-Female,
pubmed-meshheading:9667248-Humans,
pubmed-meshheading:9667248-Interferon-alpha,
pubmed-meshheading:9667248-Lymphoma, Follicular,
pubmed-meshheading:9667248-Male,
pubmed-meshheading:9667248-Middle Aged,
pubmed-meshheading:9667248-Prednisone,
pubmed-meshheading:9667248-Quality-Adjusted Life Years,
pubmed-meshheading:9667248-Recombinant Proteins,
pubmed-meshheading:9667248-Survival Analysis,
pubmed-meshheading:9667248-Teniposide
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
|
|
pubmed:affiliation |
Dartmouth Medical School, Lebanon, NH 03756, USA. bernard.f.cole@dartmouth.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
